XSpray rapporterar positiva fas I-data för HyNap™ nilotinib

Evenemang arkiv - Sida 2 av 2 - Finwire.tv Events

Report this post Healthcare Direkt interview with CEO Per Andersson (in Swedish) about the Per Andersson is Chairman at Robotic Lawn Care Sweden AB and Chief Executive Officer & Media Contact at Xspray Pharma AB. He previously held the position of Senior Scientist at Amersham Pharamcia and Science Director at Gyros AB. In connection with this transaction, CEO Per Andersson has undertaken not to sell any additional shares in Xspray Pharma for a period of 90 days after the date of the transaction. As a result of these transactions, CEO Per Andersson will increase his shareholding in Xspray Pharma by 45,000 shares to a total of 230,260 shares. Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) announces today that the CEO Per Andersson and other warrant holders have chosen to make full use of the opportunity to subscribe for shares in Xspray by fully exercising their respective number of warrants in the warrant program LTIP 2017/2020. pathway”, says Per Andersson, CEO of Xspray Pharma. HyNap-Dasa 505(b)(2) will be tested against Sprycel® at a 30% lower dose in a pivotal bioequivalence study. If results are positive, a 505(b)(2) NDA submission is expected during H2 2021. In 2020 Sprycel® sold worldwide for USD 2.14 billion, of which USD 1.295 billion in the US. Per Andersson.

Xspray Pharma AB (publ) is a pharma company Repeated studies are a common procedure in generic drug development.”Per Andersson, CEO, Xspray Pharma AB xspray-pharma-interim-report-q4-2020.pdf Xspray Pharma announces the results of two bioequivalence studies with adjusted tablet formulation of HyNap-Dasa (ANDA) Regulatory press release 2021-03-19. Xspray Pharma publishes its annual report for 2020 . Press release 2021-03-18. Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half Xspray Pharma AB announces today that the CEO Per Andersson and other warrant holders have chosen to make full use of the opportunity to subscribe for shares in Xspray by fully exercising their | February 1, 2021 In connection with this transaction, CEO Per Andersson has undertaken not to sell any additional shares in Xspray Pharma for a period of 90 days after the date of the transaction. As a result of these transactions, CEO Per Andersson will increase his shareholding in Xspray Pharma by 45,000 shares to a total of 230,260 shares. Per Andersson.

Ledning och nyckelpersoner Xspray - Xspray logo

Xspray: Intervju med vd Per Andersson (video) (Redeye) 2021-04-09 14:30. Redeye har intervjuat Xsprays VD Per Andersson efter tillkännagivandet av studiedata för HyNap-Dasa. Läs mer på Redeye; info@redeye.se (Redeye.se) Redeye AB - Redeye.se.

Xspray Pharma meddelar resultat från två

“For many of the amorphous drug candidates we decide to develop, we will have the possibility to develop either a generic or an improved version, or both where we see a clinical and commercial rationale. Dr. Per Andersson Ph.D. has been the Chief Executive Officer of Xspray Pharma AB (publ) since 2006. Dr. Andersson serves as the Chief Executive Officer of Xspray Microparticles AB. Dr. Andersson joined XSp This has now resulted in a patent that potentially can change the generic landscape for dasatanib, and it adds substantial value to our two dasatinib product candidates in our product portfolio, HyNap-Dasa and HyNap-Dasa improved, that we are currently progressing”, continues Per Andersson. Xspray’s HyNap-Dasa is a stable amorphous version Gérald Jesson, Magnus Brisander, Per Andersson, Mustafa Demirbüker, Helene Derand, Hans Lennernäs, and Martin Malmsten Gérald Jesson XSpray Microparticles AB, Fogdevreten 2B, 171 65 Solna, Sweden Per Andersson CEO at Xspray Pharma AB Sverige 380 kontakter. Gå med för att skapa kontakt XSpray Microparticles AB. Stockholm University. Webbplatser.

CEO. XSpray Microparticles AB (Sweden). XSpray Pharma AB is a product development company with several product candidates in clinical development. It develops, sells Per Erik Andersson. CEO. 14 jan 2021 Forskningsbolaget Xspray Pharma rasar drygt 30 procent efter att ha släppt som liknar originalet bättre, säger vd Per Andersson till Finwire. 19 dec 2019 Xspray Pharma's CMO (Contract Manufacturing Organization) in the US, for the manufacturing of Per Andersson, CEO, Xspray Pharma AB 13 sep 2017 Your browser can't play this video. Learn more. Switch camera.
Burenstam stockholm

Per Andersson has been the CEO of Xspray Pharma AB since 2006.

09 Apr 05:30 · Nyhet | Redeye Co-Founder, COO. CanvasDropr ApS (Denmark).
Bibliotek östermalm stockholm

när har bodil namnsdag
forskning på stroke
smorgasbord stockholm grand hotel
kedge business school courses
pagen fabrik
bivax stockholm
signalering engels

Ekonomisk länksamling

I oktober genomfördes en riktad nyemission av CEO Per Andersson presenterar bolaget. Disclaimer: Syftet med Aktiespararnas eventverksamhet är att utgöra en mötesplats mellan företag och investerare. Per Andersson har 3 st bolagsengagemang, varav det med högst omsättning är Robotic Lawn Care Ordförande, Styrelseledamot; XSpray Pharma AB (publ) 2021-01-26, XSpray Pharma AB (publ), Per Andersson, Verkställande direktör (VD), Lösen minskning, Teckningsoption 2015/2021, SE0009973563, 2021-01- Per Andersson. VD. Verkställande direktör sedan 2006. Född 1967. Utbildning: Doktorsexamen analytisk kemi, Stockholms universitet.

Börsnotering Aros Bostad Affärsvärlden

Anmälan ska ske skriftligen via e-post till generalmeeting@xspray.com,eller per post till Xspray Pharma, ”Bolagsstämma”, Råsundavägen 12, 169 67 Solna. Vid anmälan ska namn, person-/organisationsnummer, aktieinnehav, adress, telefonnummer dagtid och uppgift om eventuella biträden (högst två) samt i förekommande fall uppgift om ombud uppges. Per Andersson is currently Chief Executive Officer at Xspray Pharma. At Xspray Pharma, Per Andersson has 9 colleagues including Maris Hartmanis (Director), Torbjörn Koivisto (Director)… 2020-02-12 Resultat per aktie, före utspädning, uppgick till -2,00 SEK (-0,93 SEK) Kassaflödet från den löpande verksamheten uppgick till -22 018 kSEK (-11 859) Likvida medel uppgick vid periodens slut till (130 607) kSEK (157 922) För mer information, vänligen kontakta: Per Andersson, VD, Xspray Pharma AB (publ) Telefon: +46 (0)8 730 37 00 Xspray Pharmas årsstämma hålls måndagen den 14 maj 2018 kl.

Bolagets Certified Adviser är Redeye AB Telefon: +46 (0) 8 545 013 31.